Gender minorities in breast cancer - Clinical trials enrollment disparities : Focus on male, transgender and gender diverse patients
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in BC phase III registration clinical trials.
METHODS: We conducted a scoping review of phase III clinical trials of agents with a current positioning within the therapeutic algorithms of BC.
RESULTS: We selected 51 phase III trials. Men enrollment was allowed in 35.3% of trials. In none of the trial inclusion/exclusion criteria referred to transgender/gender-diverse people. A numerical higher rate of enrolled men was observed in the contemporary as compared to historical group. We found a statistically significant association between the drug class and the possibility of including men: 100%, 80%, 50%, 33.3%, 25%, 10% and 9.1% of trials testing ICI/PARP-i, ADCs, PI3K/AKT/mTOR-i, anti-HER2 therapy, CDK4/6-i, ET alone, and CT alone. Overall, 77409 patients were enrolled, including 112 men (0.2%). None of the trial reported transgender/gender-diverse people proportion. Studies investigating PARP-i were significantly associated with the highest rate of enrolled men (1.42%), while the lowest rates were observed for trials of CT (0.13%), ET alone (0.10%), and CDK 4/6-I (0.08%), p < 0.001.
CONCLUSIONS: We confirmed that gender minorities are severely underrepresented among BC registration trials. We observed a lower rate of men in trials envisaging endocrine manipulation or in less contemporary trials. This work sought to urge the scientific community to increase the awareness level towards the issue of gender minorities and to endorse more inclusive criteria in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Breast (Edinburgh, Scotland) - 75(2024) vom: 09. März, Seite 103713 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miglietta, Federica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Revised 25.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.breast.2024.103713 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369832736 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369832736 | ||
| 003 | DE-627 | ||
| 005 | 20240325235241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2024.103713 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM369832736 | ||
| 035 | |a (NLM)38493590 | ||
| 035 | |a (PII)S0960-9776(24)00044-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miglietta, Federica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gender minorities in breast cancer - Clinical trials enrollment disparities |b Focus on male, transgender and gender diverse patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in BC phase III registration clinical trials | ||
| 520 | |a METHODS: We conducted a scoping review of phase III clinical trials of agents with a current positioning within the therapeutic algorithms of BC | ||
| 520 | |a RESULTS: We selected 51 phase III trials. Men enrollment was allowed in 35.3% of trials. In none of the trial inclusion/exclusion criteria referred to transgender/gender-diverse people. A numerical higher rate of enrolled men was observed in the contemporary as compared to historical group. We found a statistically significant association between the drug class and the possibility of including men: 100%, 80%, 50%, 33.3%, 25%, 10% and 9.1% of trials testing ICI/PARP-i, ADCs, PI3K/AKT/mTOR-i, anti-HER2 therapy, CDK4/6-i, ET alone, and CT alone. Overall, 77409 patients were enrolled, including 112 men (0.2%). None of the trial reported transgender/gender-diverse people proportion. Studies investigating PARP-i were significantly associated with the highest rate of enrolled men (1.42%), while the lowest rates were observed for trials of CT (0.13%), ET alone (0.10%), and CDK 4/6-I (0.08%), p < 0.001 | ||
| 520 | |a CONCLUSIONS: We confirmed that gender minorities are severely underrepresented among BC registration trials. We observed a lower rate of men in trials envisaging endocrine manipulation or in less contemporary trials. This work sought to urge the scientific community to increase the awareness level towards the issue of gender minorities and to endorse more inclusive criteria in clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Gender diversity | |
| 650 | 4 | |a Gender minorities | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Transgender and gender diverse people | |
| 700 | 1 | |a Pontolillo, Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a De Angelis, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Caputo, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Marino, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Bria, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Rienzo, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Verrazzo, Annarita |e verfasserin |4 aut | |
| 700 | 1 | |a Buonerba, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Tortora, Giampaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lorenzo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliano, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Montemurro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Puglisi, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Guarneri, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a De Laurentiis, Michelino |e verfasserin |4 aut | |
| 700 | 1 | |a Scafuri, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Arpino, Grazia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast (Edinburgh, Scotland) |d 1997 |g 75(2024) vom: 09. März, Seite 103713 |w (DE-627)NLM091676371 |x 1532-3080 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2024 |g day:09 |g month:03 |g pages:103713 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.breast.2024.103713 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2024 |b 09 |c 03 |h 103713 | ||